ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia

BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a debilitating disease with few treatment options. Progress towards new therapies requires validated disease biomarkers, but there is no consensus on which fluid-based measures are most informative. METHODS: This study analyzed microarray data deriv...

Descripción completa

Detalles Bibliográficos
Autores principales: Swindell, William R., Kruse, Colin P. S., List, Edward O., Berryman, Darlene E., Kopchick, John J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530130/
https://www.ncbi.nlm.nih.gov/pubmed/31118040
http://dx.doi.org/10.1186/s12967-019-1909-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6530130/
https://www.ncbi.nlm.nih.gov/pubmed/31118040
http://dx.doi.org/10.1186/s12967-019-1909-0

Ejemplares similares